Cargando…

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer

PURPOSE: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorectal cancer (mCRC), is gaining attention because ineffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osumi, Hiroki, Takashima, Atsuo, Ooki, Akira, Yoshinari, Yuri, Wakatsuki, Takeru, Hirano, Hidekazu, Nakayama, Izuma, Okita, Natsuko, Sawada, Ryoichi, Ouchi, Kota, Fukuda, Koshiro, Fukuoka, Shota, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Shoji, Hirokazu, Kato, Ken, Ishizuka, Naoki, Boku, Narikazu, Yamaguchi, Kensei, Shinozaki, Eiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319337/ https://www.ncbi.nlm.nih.gov/pubmed/37364334 http://dx.doi.org/10.1016/j.tranon.2023.101718

Ejemplares similares

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
por: Fukuda, Koshiro, et al.
Publicado: (2023)

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
por: Shimozaki, Keitaro, et al.
Publicado: (2023)

Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
por: Osumi, Hiroki, et al.
Publicado: (2020)

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2021)

Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
por: Nakayama, Izuma, et al.
Publicado: (2022)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
por: Takahari, Daisuke, et al.
Publicado: (2020)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study
por: Takahari, Daisuke, et al.
Publicado: (2023)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2017)

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
por: Udagawa, Shohei, et al.
Publicado: (2023)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma
por: Nakayama, I., et al.
Publicado: (2023)

A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
por: Shimozaki, K., et al.
Publicado: (2021)

Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases
por: Harada, Kazuaki, et al.
Publicado: (2023)

Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study
por: Ishikawa, Masashi, et al.
Publicado: (2021)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab
por: Kadono, Toru, et al.
Publicado: (2023)

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
por: Ooki, Akira, et al.
Publicado: (2021)

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
por: Watanabe, Sho, et al.
Publicado: (2017)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_79qcrh70d0k9rn9em4jikgos92